Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma.
Peat TJ, Gaikwad SM, Dubois W, Gyabaah-Kessie N, Zhang S, Gorjifard S, Phyo Z, Andres M, Hughitt VK, Simpson RM, Miller MA, Girvin AT, Taylor A, Williams D, D'Antonio N, Zhang Y, Rajagopalan A, Flietner E, Wilson K, Zhang X, Shinn P, Klumpp-Thomas C, McKnight C, Itkin Z, Chen L, Kazandijian D, Zhang J, Michalowski AM, Simmons JK, Keats J, Thomas CJ, Mock BA. Peat TJ, et al. Among authors: flietner e. Cancer Lett. 2023 Aug 1;568:216284. doi: 10.1016/j.canlet.2023.216284. Epub 2023 Jun 24. Cancer Lett. 2023. PMID: 37356470
Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment.
Papadas A, Deb G, Cicala A, Officer A, Hope C, Pagenkopf A, Flietner E, Morrow ZT, Emmerich P, Wiesner J, Arauz G, Bansal V, Esbona K, Capitini CM, Matkowskyj KA, Deming DA, Politi K, Abrams SI, Harismendy O, Asimakopoulos F. Papadas A, et al. Among authors: flietner e. Cell Rep. 2022 Aug 16;40(7):111201. doi: 10.1016/j.celrep.2022.111201. Cell Rep. 2022. PMID: 35977482 Free PMC article.
Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model.
Flietner E, Wen Z, Rajagopalan A, Jung O, Watkins L, Wiesner J, You X, Zhou Y, Sun Y, Kingstad-Bakke B, Callander NS, Rapraeger A, Suresh M, Asimakopoulos F, Zhang J. Flietner E, et al. Sci Rep. 2022 Jun 23;12(1):10616. doi: 10.1038/s41598-022-14114-z. Sci Rep. 2022. PMID: 35739276 Free PMC article.
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
You X, Liu F, Binder M, Vedder A, Lasho T, Wen Z, Gao X, Flietner E, Rajagopalan A, Zhou Y, Finke C, Mangaonkar A, Liao R, Kong G, Ranheim EA, Droin N, Hunter AM, Nikolaev S, Balasis M, Abdel-Wahab O, Levine RL, Will B, Nadiminti KVG, Yang D, Geissler K, Solary E, Xu W, Padron E, Patnaik MM, Zhang J. You X, et al. Among authors: flietner e. Blood. 2022 Feb 17;139(7):1066-1079. doi: 10.1182/blood.2021012519. Blood. 2022. PMID: 34699595 Free PMC article.
Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice.
Wen Z, Rajagopalan A, Flietner ED, Yun G, Chesi M, Furumo Q, Burns RT, Papadas A, Ranheim EA, Pagenkopf AC, Morrow ZT, Finn R, Zhou Y, Li S, You X, Jensen J, Yu M, Cicala A, Menting J, Mitsiades CS, Callander NS, Bergsagel PL, Wang D, Asimakopoulos F, Zhang J. Wen Z, et al. Among authors: flietner ed. Blood. 2021 Jan 7;137(1):61-74. doi: 10.1182/blood.2020007156. Blood. 2021. PMID: 32640012 Free PMC article.
Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma.
Dhakal B, Pagenkopf A, Mushtaq MU, Cunningham AM, Flietner E, Morrow Z, Papadas A, Hope C, Leith C, Hematti P, Hari P, Callander NS, Asimakopoulos F. Dhakal B, et al. Among authors: flietner e. Leuk Lymphoma. 2019 Oct;60(10):2558-2562. doi: 10.1080/10428194.2019.1585836. Epub 2019 Mar 8. Leuk Lymphoma. 2019. PMID: 30845856 Free PMC article. No abstract available.